These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 29248520)

  • 1. New therapies for atopic dermatitis: Additional treatment classes.
    Vakharia PP; Silverberg JI
    J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S76-S83. PubMed ID: 29248520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of the histamine H
    Werfel T; Layton G; Yeadon M; Whitlock L; Osterloh I; Jimenez P; Liu W; Lynch V; Asher A; Tsianakas A; Purkins L
    J Allergy Clin Immunol; 2019 May; 143(5):1830-1837.e4. PubMed ID: 30414855
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamic Effects of Topical Omiganan in Patients With Mild to Moderate Atopic Dermatitis in a Randomized, Placebo-Controlled, Phase II Trial.
    Niemeyer-van der Kolk T; van der Wall H; Hogendoorn GK; Rijneveld R; Luijten S; van Alewijk DCJG; van den Munckhof EHA; de Kam ML; Feiss GL; Prens EP; Burggraaf J; Rissmann R; van Doorn MBA
    Clin Transl Sci; 2020 Sep; 13(5):994-1003. PubMed ID: 32315497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atopic dermatitis treatment: Current state of the art and emerging therapies.
    Silverberg JI
    Allergy Asthma Proc; 2017 Jul; 38(4):243-249. PubMed ID: 28668106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative efficacy of systemic treatments for atopic dermatitis.
    Seger EW; Wechter T; Strowd L; Feldman SR
    J Am Acad Dermatol; 2019 Feb; 80(2):411-416.e4. PubMed ID: 30296535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Revisiting Therapies for Atopic Dermatitis that Failed Clinical Trials.
    Agnihotri G; Lio PA
    Clin Drug Investig; 2020 May; 40(5):421-431. PubMed ID: 32172523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal Antibodies for Atopic Dermatitis: Progress and Potential.
    Vakharia PP; Silverberg JI
    BioDrugs; 2017 Oct; 31(5):409-422. PubMed ID: 28853008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel topical and systemic therapies in atopic dermatitis.
    Suga H; Sato S
    Immunol Med; 2019 Jun; 42(2):84-93. PubMed ID: 31318324
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IL-4 and IL-13 Inhibition in Atopic Dermatitis.
    Matsunaga MC; Yamauchi PS
    J Drugs Dermatol; 2016 Aug; 15(8):925-9. PubMed ID: 27537991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adult atopic dermatitis: new and emerging therapies.
    Napolitano M; Marasca C; Fabbrocini G; Patruno C
    Expert Rev Clin Pharmacol; 2018 Sep; 11(9):867-878. PubMed ID: 30073901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE).
    Simpson EL; Flohr C; Eichenfield LF; Bieber T; Sofen H; Taïeb A; Owen R; Putnam W; Castro M; DeBusk K; Lin CY; Voulgari A; Yen K; Omachi TA
    J Am Acad Dermatol; 2018 May; 78(5):863-871.e11. PubMed ID: 29353026
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New and emerging targeted systemic therapies: a new era for atopic dermatitis.
    Lee DE; Clark AK; Tran KA; Shi VY
    J Dermatolog Treat; 2018 Jun; 29(4):364-374. PubMed ID: 28853956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical tacrolimus in the treatment of atopic dermatitis.
    Gianni LM; Sulli MM
    Ann Pharmacother; 2001; 35(7-8):943-6. PubMed ID: 11485148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review of Systemic Treatment Options for Adult Atopic Dermatitis.
    Gooderham M; Lynde CW; Papp K; Bourcier M; Guenther L; Gulliver W; Hong CH; Poulin Y; Sussman G; Vender R
    J Cutan Med Surg; 2017; 21(1):31-39. PubMed ID: 27635033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibodies against interleukin 13 and interleukin 31RA in development for atopic dermatitis.
    Hamann CR; Thyssen JP
    J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S37-S42. PubMed ID: 29248521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphodiesterase 4 inhibitors.
    Zebda R; Paller AS
    J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S43-S52. PubMed ID: 29248522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Targeted Biological Agents for the Treatment of Atopic Dermatitis.
    Yang N; Chen Z; Zhang X; Shi Y
    BioDrugs; 2021 Jul; 35(4):401-415. PubMed ID: 34213742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New and emerging therapies for paediatric atopic dermatitis.
    Vakharia PP; Silverberg JI
    Lancet Child Adolesc Health; 2019 May; 3(5):343-353. PubMed ID: 30904349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.
    Hultsch T; Kapp A; Spergel J
    Dermatology; 2005; 211(2):174-87. PubMed ID: 16088174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review and analysis of biologic therapies currently in phase II and phase III clinical trials for atopic dermatitis.
    Uppal SK; Kearns DG; Chat VS; Han G; Wu JJ
    J Dermatolog Treat; 2022 Mar; 33(2):626-636. PubMed ID: 32507066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.